Nearly two years have passed since the FDA approved (on April 29, 2010) sipuleucel-T—a therapeutic cancer vaccine developed and marketed by Dendreon Corp. as Provenge—for the treatment of patients with asymptomatic or minimally symptomatic metastatic hormone-refractory prostate cancer (HRPC). In clinical studies, this immunotherapy, which is prepared specifically for each patient, was shown to prolong survival of such patients by an average of about four months at a cost of $93,000 for each course of therapy.

Renal & Urology News would like to get an idea of the extent to which this treatment has been embraced by urologists, so please take a few moments to answer the following poll question.

Have you ever prescribed sipuleucel-T for a prostate cancer patient?
Leave a comment below to explain your choice.

Continue Reading